id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-331114-lumfg138	Berkman, Samuel A	Methodological Issues and Controversies in COVID-19 Coagulopathy: A Tale of Two Storms	2020-09-03		.txt	text/plain	6281	356	43	Despite these limitations, several societies including ASH 16 and ISTH 17 and the Anti-coagulation Forum 18 have recommended at least prophylactic dose anticoagulation for any hospitalized COVID patient without excessive bleeding risk or other contraindications. Conflicting guidelines have been released regarding escalation to full-dose heparinization with either unfractionated or low molecular weight heparin (LMWH) in patients who are deteriorating on either low-or intermediate-dose prophylaxis, particularly those on ventilators, without documented diagnoses of pulmonary embolism (PE) or deep venous thrombosis (DVT) (Table one) This strategy is reinforced by the low incidence of bleeding observed in COVID patients compared with other causes of DIC such as obstetrical ones. Unless a physician can say that they would not prescribe anti-coagulation for an asymptomatic proximal venous thrombosis in a COVID patient, it would seem inappropriate to issue a strong negative guideline on post-hospital discharge prophylaxis in these patients given their unique hypercoagulable predispositions.	./cache/cord-331114-lumfg138.txt	./txt/cord-331114-lumfg138.txt